Results 181 to 190 of about 1,783,252 (315)

Elevated Hemoglobin Levels and Risk of ST‐Segment Elevation Myocardial Infarction in High‐Altitude Acute Coronary Syndrome: A Retrospective Analysis

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background High‐altitude populations typically exhibit elevated hemoglobin (Hb) levels due to chronic hypoxic exposure; however, the impact of this elevation on the risk of ST‐segment elevation myocardial infarction (STEMI) remains unclear. Existing evidence is primarily derived from low‐altitude populations and cannot be directly extrapolated
Jing Li   +10 more
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich   +5 more
wiley   +1 more source

Haemoglobin variants in nigeria: real-world data from a point-of-care device. [PDF]

open access: yesAnn Hematol
Kotila T   +8 more
europepmc   +1 more source

Drug Repositioning of Pegbing® for Essential Thrombocythemia: Insights from PK/PD Modeling and Extrapolation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pegbing® (peginterferon alfa‐2b), a pegylated interferon‐alpha, is approved for the treatment of chronic hepatitis B (CHB) and C. One of its adverse effects is platelet (PLT) suppression. It is currently being repurposed for the treatment of essential thrombocythemia (ET), a rare myeloproliferative disorder characterized by abnormally elevated PLT ...
Weizhe Jian   +7 more
wiley   +1 more source

Clinical and hematological characteristics of beta-plus thalassemia and uncommon beta-chain hemoglobin variants in Northern Thailand. [PDF]

open access: yesAnn Med
Rukwong P   +7 more
europepmc   +1 more source

Breaking Barriers: Characterization of the Intradermal Lipopolysaccharide Challenge as an In Vivo Model for Controlled Induction of Vascular Leakage in Healthy Volunteers

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Vascular leakage and its associated phenomena vasodilation and endothelial activation are pathophysiological features of various diseases. Multiple drug candidates targeting these phenomena are in development, necessitating translational models to demonstrate proof‐of‐pharmacology and proof‐of‐mechanism in early‐phase clinical trials.
Marella Cornelia Elizabeth van Ruissen   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy